The EMPA-REG outcome study: critical appraisal and potential clinical implications

Gianluca Perseghin and Anna Solini

Abstract
Diabetes health care professionals have to face a study with results of incomparable success in secondary and tertiary cardiovascular disease prevention. In the past, no studies in patients with type 2 diabetes resulted to be successful in inducing an improvement of cardiovascular prognosis, no matter whether they were focused on a target, on lifestyle or on pharmacological intervention. On a clinical perspective, should the diabetologist’s way to think about the anti-diabetic therapy of patients on secondary cardiovascular prevention change based on the results of Empa-REG outcome? Due to the complexity of the clinical picture of patients with type 2 diabetes, a tailored therapy based on targets, complications, co-morbidity, familial and social environment, personal and cultural features must be conceived and applied in starting pharmacological therapy; however, the question whether should we consider empagliflozin as first choice therapy in individuals with type 2 diabetes exposed to high cardiovascular risk, the Empa-REG outcome-like patient, awaits now for an answer. Waiting for data confirming the results of the Empa-REG outcome study, this report goes through the good reasons in support of this way of thinking, but at the same time explores the many unanswered questions raising potential concerns about this clinical choice.

Keywords: Cardiovascular safety, Hypoglycemic agents, Type 2 diabetes, Empagliflozin

Brief summary of the study

Aim and patients

- **Aim**: To test the non-inferiority of empagliflozin vs placebo in terms of cardiovascular (CV) safety.
- **Patients**: 7020 type 2 diabetes (T2DM) individuals with established CV disease (defined as the presence of ≥1 of the following: history of myocardial infarction; documented multi-vessel coronary artery disease; documented single-vessel coronary artery disease with ≥50 % luminal narrowing plus positive non-invasive stress test for ischemia or recent hospital discharge for unstable angina; documented unstable angina; history of ischemic or hemorrhagic stroke; occlusive peripheral artery disease), randomized to placebo, empagliflozin 10 or 25 mg as add-on to the usual therapy.

- Patients allocated in the three arms were comparable for age, gender, BMI and HbA1c; blood pressure (BP) and LDL-cholesterol levels (mean 135/77 mmHg and 85–86 mg/dl, respectively) were in a reasonably good control; 95 % of them assumed antihypertensive drugs, 80 % hypolipidemic drugs and 83 % anti-platelets drugs.
- **Median treatment duration**: 2.6 years; median observation time 3.1 years.
- **Statistical analysis**: intention-to-treat, comparing response to empagliflozin 10 and 25 mg vs placebo in all subjects receiving at least one treatment dose; non-inferiority analysis, with a HR border of 1.3 vs placebo for primary and secondary endpoint; superiority was tested as eventual following step.

Results

- **HbA1c** At the end of the study HbA1c reduction was 0.24 % with 10 mg and 0.36 % with 25 mg empagliflozin vs placebo.
• **Body weight** Patients randomized to empagliflozin showed a significant reduction in body weight (2–3 kg with empagliflozin 25 mg).

• **Arterial BP and heart rate** Empagliflozin induced a prompt reduction of systolic BP (4–6 mmHg vs placebo at week 16), which was maintained along the time. At the end of the study diastolic BP did not differ from placebo. A higher percent of placebo-treated patients required a potentiation of the background anti-hypertensive therapy. No difference in the heart rate was observed.

• **Lipid profile and uric acid** Active treatment induced an initial raise in LDL-cholesterol (3–4 mg/dl vs placebo), which resulted to be negligible after 52 weeks. HDL-cholesterol showed a similar trend in the three arms. The uricosuric effect of empagliflozin was confirmed.

The main results of the study in terms of CV endpoints are shown in Table 1. The effects on hard endpoints did not differ in the two empagliflozin arms.

The **Empa-Reg outcome** is a rewarding study with respect to other clinical trials comparing a specific anti-hyperglycemic drugs vs placebo in terms of CV endpoints

It is difficult to compare studies performed in different historical periods, with different aims, and in patients with different clinical characteristics and concomitant treatments; however, an attempt to compare Empa-Reg outcome [1] with recent clinical studies aimed at assessing non inferiority of other novel anti-diabetic drugs respect to traditional, established therapies, is imperative.

The **PROactive study** tested the efficacy of pioglitazone in reducing CV morbidity and mortality in high CV risk T2DM patients [2]. The primary endpoint (all-cause mortality, non-fatal MI, non-fatal stroke, acute coronary syndrome, revascularization procedures or lower limb amputation) was not achieved, in contrast with a matched secondary endpoint (CV death, MI, stroke). The study was characterized by an excess of non-fatal heart failure (HF) but it should be emphasized that HF was not an adjudicated end-point and that cases of HF resulted to have fewer CV events than those observed in the placebo group, raising doubt about the incidence of a true HF which could be misclassified in the place of peripheral edema. Moreover, the only endpoint with unfavorable outcome was the procedure of peripheral revascularization, in contrast with the effect on MACE which was consistently a positive one.

The **Origin study** tested the efficacy of glargine in reducing CV morbidity in T2DM patients with whatever background therapy, including insulin [3]. Characteristics of the participants were different from those of Empa-Reg outcome, being patients with altered glucose tolerance or recent onset diabetes even though approximately 60 % of them were on secondary CV prevention. The trial generated a neutral result in terms of coprimary endpoints (nonfatal MI, nonfatal stroke, or death from CV causes and these events plus revascularization or hospitalization for heart failure.), even if it should be underlined that the daily insulin use resulted to be about 30 IU per day, likely due to very short duration of the disease. Some patients, especially those with a longer duration, may require a significantly higher amount of insulin and in our opinion this condition remains to be tested in terms of CV safety.

### Table 1 Cardiovascular results of the Empa-Reg outcome study

| Endpoint                              | Empagliflozin (all together) | Placebo       | HR 95 % CI      | Non inferiority | Superiority |
|---------------------------------------|------------------------------|---------------|-----------------|-----------------|-------------|
| Primary endpoint                      | 490/4687 (10.5 %)            | 282/2333 (12.1 %) | 0.86            | 0.74–0.99       | P < 0.001   | P = 0.04   |
| Key secondary endpoint                | 599/4687 (12.8 %)            | 333/2333 (14.3 %) | 0.89            | 0.78–1.01       | P < 0.001   | P = 0.08   |
| Cardiovascular death                  | 172/4687 (3.7 %)             | 137/2333 (5.9 %) | 0.62            | 0.49–0.77       | N.A.        | P < 0.001  |
| Non-fatal myocardial infarction       | 213/4687 (4.5 %)             | 121/2333 (5.2 %) | 0.87            | 0.70–1.09       | N.A.        | P = 0.22   |
| Non-fatal stroke                      | 150/4687 (3.2 %)             | 60/2333 (2.6 %)  | 1.24            | 0.92–1.67       | N.A.        | P = 0.16   |
| Heart failure                         | 126/4687 (2.7 %)             | 95/2333 (4.1 %)  | 0.65            | 0.50–0.85       | N.A.        | P = 0.002  |
| All-cause death                       | 269/4687 (5.7 %)             | 194/2333 (8.3 %) | 0.68            | 0.57–0.82       | N.A.        | P = 0.001  |

*Primary endpoint: standard 3 endpoint-MACE (CV death, non-fatal myocardial infarction (MI), non-fatal stroke); pre-specified key secondary endpoints: time to first event (CV death, non-fatal MI, non-fatal stroke, hospitalization for unstable angina)*

*N.A. not applicable*
Savor-TIMI [4], Examine [5] and Tecos [6] tested the effects of the DPP-IV inhibitors saxagliptin, aloglip- 
tin and sitagliptin on CV safety, to demonstrate their 
non-inferiority with respect to placebo, as requested by 
regulatory authorities. Recruited patients differed for 
clinical characteristics: high CV risk patients in Savor-
TIMI; individuals with recent acute coronary syndrome 
in Examine; relatively low CV risk patients in Tecos. 
We interpret the general findings of these studies as a 
demonstration of DPP-IV inhibitors neutrality on CV 
risk, though a higher risk of hospitalization for HF was 
detected in SAVOR-TIMI and for some authors, based 
on retrospective calculations of the sample size, also 
in Examine. These correlative findings highlighted the 
potential relation between anti-hyperglycemic therapies 
and risk of HF, probably due to the link with the weight 
gain often associated with this treatment [7]. More 
recently at least three very large studies reported no 
effects of DPP-IV inhibitors when tested retrospectively 
clinical setting [8, 9] or very small effects [10]. 

Studies evaluating the effects of GLP-1 analogues will 
ready contribute to clarify this important issue. At 
this stage Elixa [11], performed in patients with recent 
acute coronary syndrome, documented the CV safety of 
lisixenatide when compared to placebo, and we are now 
waiting for the publication of the results of the LEADER 
trial, also testing CV safety of one of another GLP1-RA, 
liraglutide, which is expected in the next few weeks.

EMPA REG outcome is a relevant success also with respect 
to trials comparing conventional vs intensive strategies 
of glucose control on CV endpoints 
Since the UKPDS study has been published [12], the 
international community is still debating whether or not 
optimizing glucose control could reduce CV risk. To 
address this question, three main large randomized clini-
cal trials were completed, aimed at verifying whether or 
not an improved metabolic control (irrespective of how 
this was obtained) could be associated with a better CV 
outcome: ACCORD [13], ADVANCE [14] and VADT 
[15]. It is well known that these studies have generated 
negative results and frustration, even if they resulted to 
be very useful in inducing a change in the vision of how 
we have to treat our patients, emphasizing the need for a 
“tailored therapy” able to address the individual needs of 
each single patient, especially with respect to the targets 
to pursue. 

A common thinking is that an intensive anti-hyper-
glycemic therapy can be deleterious on mortality rate of 
frail individuals, therefore neutralizing potential CV 
benefits [13, 15]; however, it should be noticed that the 
prolonged observation of the individuals participating to 
two of those trials [16, 17] detected, in the post-trial 
observational period, that patients treated more inten-
sively had a reduced CV risk which took longer than it was 
thought, confirming the previously reported and 
similar findings of the follow-up of the UKPDS study 
[18]. 

Also when combined physical exercise and nutritional 
therapy were the selected strategy to improve glucose 
control, as it was tested in the Look Ahead study, a CV 
benefit could not be detected [19]. Only the PREDIMED 
study [20], which tested the cardiovascular impact of the 
Mediterranean Diet, reported some positive results. It 
this study 7447 persons at high CV risk (with and with-
out diabetes), but without CV disease at baseline were 
randomized to three different dietary regimens: standard 
traditional diet, Mediterranean diet enriched with olive 
and nuts and almonds. Primary end-point was the 
clinical cardiovascular death, non fatal MI and non fatal stroke. Even if the nutritional inter-
vention had no effect on mortality, it showed a clear-cut 
positive effect on CV events which could be observed 
early during the observational period suggesting that the 
nutritionally-induced benefit could be mediated via 
anti-inflammatory effect.

The mechanisms by which empagliflozin determined the 
CV protection observed in the Empa-Reg outcome remain, 
so far, obscure 
Empa-Reg outcome is a successful clinical study, opening 
new scenarios but also leaving unsolved several ques-
tions. Mechanistically, it is unclear how the treatment 
could determine such CV benefit. Several candidates 
 might be taken into consideration. 

Anti-hyperglycemic effect in our opinion the hypothesis that the beneficial CV impact could be mediated via the 
anti-hyperglycemic effect is weak because the difference 
in HbA1c levels during the study between empagliflo-
zin treatment and placebo was too small to explain the 
outcome. More importantly, the rapid onset of the pro-
teptive effect of the treatment in the empagliflozin arms 
seems to be not compatible with a glycemic effect, which 
seems to be not compatible with the concept of 
“metabolic memory”, which was detected years after the 
treatment, not in few weeks/months, as observed in 
Empa-Reg outcome. However empagliflozin has recently 
shown a fast (24 h) efficacy in reducing post-prandial glu-
cose and improving metabolic control in Japanese T2DM 
individuals [21].

Weight loss similar explanations minimize the possibil-
ity that the positive effect could be related to the weight 
loss. Also in this case the small difference among the 
groups in terms of body weight change does not seem 
sufficient to explain such a large and rapid effect on CV
mortality; however, we should not forget that, in these high CV risk patients, rapid weight gain, potentially reflecting fluid retention, can be considered a “proxy” for the risk to develop HF [7]. However, a recent pooled analysis performed on 3300 patients receiving empagliflozin has shown its ability to reduce waist, total body fat and indexes of central and visceral adiposity, likely contributing to reduce CV risk [22]. The sustained reduction of weight loss and HbA1c might have played a role in maintaining a lower CV risk along the whole duration of the trial [23].

**BP reduction** the significant drug-induced difference in systolic BP could potentially have strongly contributed to the results; this effect is also compatible with the early divergence of the survival curves, thus playing a major role in the improved prognosis of empagliflozin-treated patients. Against this hypothesis stands the observed trend toward an increased risk of non-fatal stroke; this is surprising because stroke is the macrovascular complication that should mostly take advantage from BP reduction.

**Uricosuric effect** recently, the role of uric acid as determinant of CV disease has been postulated [24], also in the light of an association between uric acid levels and HF [25]; some studies showed the beneficial effect of lowering uric acid on CV events [26, 27], even though data are still controversial [28] and mechanisms are still unknown. On this basis, the uricosuric effect of SGLT2 inhibitors could be a potential candidate to explain CV protection even if perplexity remains with respect to the rapid onset of protection that makes difficult to sustain this metabolic hypothesis.

**Inflammation** an interesting phenomenon observed in the trial is the early opening of the rate of events, that this effect is also compatible with the early divergence of the survival curves, thus playing a major role in the improved prognosis of empagliflozin-treated patients. Against this hypothesis stands the observed trend toward an increased risk of non-fatal stroke; this is surprising because stroke is the macrovascular complication that should mostly take advantage from BP reduction.

**Inflammation** an interesting phenomenon observed in the trial is the early opening of the rate of events, that this effect is also compatible with the early divergence of the survival curves, thus playing a major role in the improved prognosis of empagliflozin-treated patients. Against this hypothesis stands the observed trend toward an increased risk of non-fatal stroke; this is surprising because stroke is the macrovascular complication that should mostly take advantage from BP reduction.

**Increased cardiac β-hydroxybutyrate uptake** it may be hypothesized that under the above conditions of stimulated glucagon release, mild, persistent hyperketonemia, like may occur during treatment with SGLT2 inhibitors as reported by Ferrannini et al. [34], β-hydroxybutyrate uptake may be freely taken up by the heart and oxidized in preference to fatty acids. This fuel selection may improve transduction of oxygen consumption into work efficiency at the mitochondrial level. In addition, the hemoconcentration that typically follows SGLT2 inhibition likely enhances oxygen release to the tissues, thereby establishing a powerful synergy with the metabolic substrate shift and finally explaining the beneficial cardiovascular effect observed in **Empa-Reg outcome**.

**RAAS-mediated effect** the vast majority of participants in the **Empa-Reg outcome** study were treated with RAAS active drugs. Combining the two regimens (RAAS blocking and SGLT2 inhibition), as already suggested to explain positive effects on the glomerular hemodynamics and nephroprotection [35], might in principle activate the AT2 receptor and the Angiotensin 1–7 pathway, with an anti-proliferative, anti-inflammatory, anti-arrhythmic, vasodilatory effect.

**Arterial stiffness** empagliflozin has been reported to reduce arterial stiffness in normotensive T1DM individuals [36] and could contribute to the beneficial CV effects. In **Empa-Reg outcome** this parameter was not measured, therefore its potential role is hypothetical and not supported by experimental data at this stage.

**Safety profile in the **Empa-Reg outcome** study** The **Empa-Reg outcome** study showed a surprising safety profile across the whole line of previously reported potential adverse events and side effects. The most insidious one, diabetic ketoacidosis, occurred rarely (0.1 %), without difference between active treatment and placebo. Similarly, elderly patients, apparently those with...
the lowest indication to use SGLT2 inhibitors, have taken advantage from the best prognosis, even though it will be important to better define the relationship between increased blood cells count and the small, not significant signal of risk of stroke. In parallel, patients with chronic kidney disease showed a documented prognostic benefit, similar to that of individuals with preserved renal function. Finally, the reported increased risk of genital tract infection was fully confirmed, though its impact on the need for drug withdrawal was small.

**Approaching other SGLT2-inhibitors studies**

To answer the question whether or not this CV protection is a class effect, or is exclusive of empagliflozin is, at this stage, a difficult task. If we postulate that the beneficial cardiovascular effect is mostly related to glucorectic/natriuretic effect and consequent volume depletion with a parallel, additional reduction of systolic BP or if we consider that it may be mediated via metabolic effects related to increased cardiac ketone bodies uptake and disposal it is likely that benefit can be considered a class-effect because they might be all able to induce these effects. Said that, different drugs may have different specificity for SGLT2 and SGLT1, opening to discussion and speculation related to many other different potentially relevant effects in terms of CV protection making potentially different the effect of each single drug within the class. For this reason we believe that it is imperative to confirm the results of Empa-Reg outcome. In few years, results from DECLARE (dapagliflozin in patients with a lower CV risk patients) and CANVAS (canagliflozin in high CV risk individuals) studies will be available, confirming or denying the role of SGLT2 inhibitors as first-class anti-diabetic drugs able to manage residual CV risk up to reduce mortality, likely independently from their glucose-lowering effect.

**Which will be the impact on microvascular complications?**

Forthcoming studies with other SGLT2 inhibitors should also address still open questions regarding the effect on microvascular complications. In fact, the anti-hyperglycemic effect of empagliflozin might still be unsatisfactory for many patients in a real-life context. In Empa-Reg outcome the HbA1c reduction of 0.3–0.4 % from baseline to the end of the trial failing to achieve the general target of <7 %, which is recognized to guarantee a robust protection against the risk to develop microvascular complication, would maintain concern with respect to this clinical issue. When considering kidney disease, Empa-Reg renal will likely answer in a while; promising preliminary data, showing a stable glomerular filtration rate across the whole study duration vs a decline in the placebo arm, were shown at the American Society of Nephrology 2015 annual meeting and we are waiting for the publication of the original article. This beneficial effect on diabetic kidney disease may be selectively explained by the capacity of empagliflozin to prevent hyperfiltration in the early stage of diabetic nephropathy as reported in patients with type 1 diabetes [37]. The question about microvascular complication would remain open with respect to diabetic retinopathy and neuropathy in which mechanistically the above mentioned protective mechanism for the kidney may result to be irrelevant for the eyes and the peripheral nervous system.

**Conclusion**

Whatever would the future scenario be, Empa-Reg outcome, with the strength of its results, can likely influence the modality how, in the last years, we have considered the available therapeutic options. Compared with other clinical trials, we face for the first time an anti-diabetic drug able to reduce the risk of death, CV death and HF. Such results have no precedents, and the clinician cannot ignore it.

The paradigm has changed after this study. When we figure out an Empa-Reg outcome-like T2DM patient, before Empa-Reg outcome we would ask ourselves which could have been the best “tailored” therapeutic intervention, on the basis of his/her individual features (age, personal clinical history, diabetes duration, glycemic target, phenotype, lifestyle, presence of complications and/or comorbidities). Now, we should establish whether in Empa-Reg-like patients there is any reason, except the presence of precise contra-indications to its use, for not considering the possibility to prescribe a drug able to improve the prognosis of our patient irrespective of its anti-hyperglycemic effect. What has been observed during the Empa-Reg outcome study remains, so far, an enigma, and it seems difficult to use a therapeutic instrument without knowing the mechanism throughout it improves CV prognosis, especially when such protection does not seem to be mediated by atherosclerosis-related mechanisms.

We are in front of a single clinical trial, even robust and well-conducted. More data will be necessary to confirm these positive effects, perhaps providing instruments to understand what has exactly happened in Empa-Reg outcome.

However, such therapeutic approach should be seriously considered because, in Empa-Reg outcome, body weight, BP, uric acid levels, risk of hypoglycemia, all go in the desired direction. The study also confirms a good safety profile, with the only concern of genital infections. Concerns on euglycemic diabetic ketoacidosis, hypoglycemia in the elderly, urinary infections, bone fractures, use in patients with impaired kidney function, vanished,
in the absence of an even minimal signal of danger. That is a striking difference when we refer to the alarms reported by FDA and EMA, and it will require a cautious clarification through future studies.

To conclude, several arguments can be provided either in favor of an enthusiastic or a more cautious interpretation of the Empa-Reg outcome results: it is too early to pretend answering to all the points raised by the study. Trying a parallelism, similarly to how intensive vs conventional treatment strategy trials had imposed a radical change in the therapeutic approach, Empa-Reg outcome challenges us, forcing to change again the clinical paradigm followed in the last years. To be provocative, we might figure out to go back to more rigid and simple therapeutic schemes, with a potentially new hierarchy of drug choice to combine with metformin at least in patients with high CV risk.

Authors’ contributions
GP and AS equally contributed in drafting the manuscript. Both authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 18 February 2016   Accepted: 25 May 2016
Published online: 04 June 2016

References
1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empa-Reg outcome investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.
2. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROSpective pioglitAzone clinical trial in macrovascular events): a randomised controlled trial. Lancet. 2005;366:1279–89.
3. ORIGIN trial investigators, Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, Maggioni AP, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319–28.
4. Sicrca BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. SAVOR-TIMI 53 Steering committee and investigators. saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–26.
5. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, EXAMINE investigators, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–35.
6. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, TECOS study group, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–42.
7. Gilbert RE, Krum H. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet. 2015;385:2107–17.
8. Fadini GP, Avogaro A, Degli Esposti L, Russo P, Saragoni S, Buda S, OsMed Health-DB Network. Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,55 patients from the nationwide osmed health-db database. Eur Heart J. 2015;36(36):2454–62.
9. Filion KB, Aozoulay L, Platt RW, Dahl M, Dormuth CR, Clemens KK, CNODES investigators, et al. A multicenter observational study of incretin-based drugs and heart failure. N Engl J Med. 2016;374:1145–54.
10. Li L, Li S, Deng K, Liu J, Vandan PO, Zhao P, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ. 2016;352:i610.
11. Jaffer MA, Ciaggett B, Diaz R, Dickstein K, Gerstein HC, Keber LJ, ELIXA investigators, et al. Liexisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–57.
12. UK prospective diabetes study (UKPDS) group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.
13. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goof DC, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.
14. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;359:2560–72.
15. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, VADT investigators, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39.
16. Gerstein HC, Miller ME, Ismail-Beigi F, Largay J, McDonald C, Lochnan HA, ACCORD Study Group, et al. Effects of intensive glycemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet. 2013;384:1936–41.
17. Hayward RA, Reaven PD, Wiltala WL, Bahn GD, Reda DJ, Ge L, et al. VADT Investigators. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372:2197–206.
18. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.
19. Look AHEAD research group, Wing RR, Bokh F, Brancati FL, Bray GA, Clark JM, Cody M, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145–54.
20. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, PREDIMED Study Investigators, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368:1290–97.
21. Nishimura R, Tanaka Y, Koiwa K, Inoue K, Hach T, Salsali A, Lund SS, Broedl UC, et al. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study. Cardiovasc Diabetol. 2015;14:11.
22. Neeland IJ, McGuire DK, Chillon R, Crowe S, Lund SS, Woerle HJ, et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2016;13:119–26.
23. Roden M, Merker L, Christiansen AV, Roux F, Salsali A, Kim G, EMPA-REG EXTEND™ MONO investigators, et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes, a double-blind extension of a Phase III randomized controlled trial. Cardiovasc Diabetol. 2015;14:15.
24. Soltani Z, Rasheed K, Kapusta DR, Reisin E. Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal? Curr Hypertens Rep. 2013;15:175–81.
25. vonLueder TG, Girerd N, Aitar D, Ageval S, Limal Z, Kanbay M, et al. High-risk myocardial infarction database initiative investigators: serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the high-risk myocardial infarction database initiative. Eur J Heart Fail. 2015;17:1144–51.
26. Maclisaac RL, Salatzki J, Higgins P, Walters MR, Padmanabhan S, Dominiczak AF, et al. Allopurinol and cardiovascular outcomes in adults with hypertension. Hypertension. 2016;67:535–40.
27. Larsen KS, Pottegård A, Lindegaard HM, Hallas J. Effect of allopurinol on cardiovascular outcomes in hyperuricemic patients: a cohort study. Am J Med. 2016;129:299–306.
28. SaltorfLarsen K, Pottegård A, Lindegaard HM, Hallas J. Impact of urate level on cardiovascular risk in allopurinol treated patients a nested case-control study. PLoS ONE. 2016;11(1):e0146172.
29. Terami N, Ogawa D, Tachibana H, Hatanaka T, Wada J, Nakatsuka A, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor,
dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS ONE. 2014;9:e100777.

30. Cheng ST, Chen L, Li SY, Mayoux E, Leung PS. The effects of empagliflozin, an SGLT2 inhibitor, on pancreatic β-cell mass and glucose homeostasis in type 1 diabetes. PLoS ONE. 2016;11:e0147391.

31. Fitchett D, Zinman B, Wanner C, Hantel S, Salsali A, EMPA-REG OUTCOME® trial investigators et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016;37:1526–34.

32. Jones BJ, Ta T, Bloom SR. Minireview: glucagon in stress and energy homeostasis. Endocrinology. 2012;153:1049–54.

33. Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124:499–508.

34. Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, et al. Shift to fatty substrates utilization in response to sodium-glucose co-transporter-2 inhibition in nondiabetic subjects and type 2 diabetic patients. Diabetes. 2016;65:1190–5.

35. Škrtić M, Cherney DZ. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr Opin Nephrol Hypertens. 2015;24:96–103.

36. Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 2014;13:28.

37. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129:587–97.